// App-Quantinova.ai

: A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Researchers

Presenter

  • M.P.Kolinsky

Principal Investigators

  • D.Bianchini

  • Z.Zafeiriou

  • N.Mehra

  • J.Mateo

  • V.Michalarea

  • R.Riisnaes

  • M.Crespo

  • I.Figueiredo

  • S.Miranda

  • D.Nava Rodrigues

  • P.Flohr

  • N.Tunariu

  • U.Banerji

  • R.Ruddle

  • A.Sharp

  • J.Welti

  • M.Lambros

  • S.Carreira

  • F.I.Raynaud

  • K.E.Swales

  • S.Plymate

  • J.Luo

  • H.Tovey

  • N.Porta

  • R.Slade

  • L.Leonard

  • E.Hall

  • J.S.de Bono

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Institute of Cancer Research, London, UK

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Department of Clinical Medicine and Surgery, Department of Translational Medical Sciences, AOU Federico II, Naples, Italy

  • University of Washington School of Medicine, Seattle, WA

  • Brady Urological Institute, John Hopkins Medical Institute, Baltimore, MD

Locations

  • United Kingdom

  • Canada

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • AZD-5363

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02525068

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved